Regeneron Announces Participation in a Panel Discussion at RBC Capital Markets Healthcare Conference
Regeneron will participate on the Delivering on the Promise of Antibody Therapies for Cancer panel on Wednesday, December 12 at 3:30 p.m. Eastern Time. The panel discussion will be broadcast live and may be accessed through the Company's web site (www.regeneron.com on the Investor Relations page, under the Presentations heading) at the time of the panel discussion. An archived version will be available after the live webcast through January 11, 2008. Additional information about Regeneron and recent news releases are available on the Regeneron worldwide web site at www.regeneron.com.
Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of cancer, eye diseases, and inflammatory diseases and has preclinical programs in other diseases and disorders.
CONTACT: Regeneron Pharmaceuticals, Inc.
Charles Poole, 914-345-7640
Vice President, Investor Relations
charles.poole@regeneron.com
or
Laura Lindsay, 914-345-7800
Corporate Communications
laura.lindsay@regeneron.com
SOURCE: Regeneron Pharmaceuticals, Inc.